Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Clinical trial NCT01752920 · COMPLETED
Trial details
- NCT number
- NCT01752920
- Sponsor
- Basilea Pharmaceutica
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-12-10
- Primary completion
- 2018-08-28
- Enrollment
- 119
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.